Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A24-35
Last updated

Report documents

  1. Extract of dossier assessment

    Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 524 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-35_en
    Download file : Extract of dossier assessment (PDF document, 524 kB, EN, not accessible)

  2. Dossier assessment

    Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 972 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-35
    Download file : Dossier assessment (PDF document, 972 kB, DE, not accessible)

Dossier assessment

Indication:

Adults with relapsed and refractory multiple myeloma who have received prior therapies and have demonstrated disease progression on the last therapy; pretreatment includes an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody

Result of dossier assessment:
  • Patients with 2 to 3 prior therapies: added benefit not proven
  • Patients with at least 4 prior therapies: added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2024-09-18 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A24-35
Commission
Commission awarded on 02.04.2024 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A24-35_en

Connected Projects

  1. Dossier assessment

    Idecabtagene vicleucel (multiple myeloma, at least 3 prior therapies) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-28
    Last updated

    Status: Withdrawn commission

  2. Dossier assessment

    Idecabtagene vicleucel (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G22-01
    Last updated

    Status: Commission completed

  3. Addendum

    Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Addendum to Project A24-35

    Project no.
    A24-81
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page